ROIV Insider Trading Activity and SEC Form 4 Filings
ROIV insider trading summary
Over the past 12 months, insiders at Roivant Sciences Ltd. (ROIV) reported 107 sales worth $781.2M by 10 insiders and no open-market purchases on SEC Form 4. Net insider selling was $781.2M.
Latest ROIV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 3, 2026 | Eric Venker | President & Immunovant CEO | Sell | $7.3M (200,000 @ $36.31) |
| Oct 28, 2026 | Eric Venker | President & Immunovant CEO | Sell | $7.3M (200,000 @ $36.59) |
| Oct 20, 2026 | Eric Venker | President & Immunovant CEO | Sell | $501K (14,144 @ $35.42) |
| Oct 20, 2026 | Eric Venker | President & Immunovant CEO | Sell | $6.5M (185,856 @ $35.09) |
| Oct 1, 2026 | Epperly Melissa B, | Director | Sell | $608K (16,850 @ $36.08) |
| Oct 1, 2026 | Epperly Melissa B, | Director | Sell | $33K (900 @ $36.57) |
| Sep 30, 2026 | Eric Venker | President & Immunovant CEO | Sell | $7.3M (200,000 @ $36.62) |
| Sep 15, 2026 | Meghan Fitzgerald | Director | Sell | $187K (4,712 @ $39.68) |
| Sep 15, 2026 | Epperly Melissa B, | Director | Sell | $172K (4,338 @ $39.65) |
| Sep 15, 2026 | Meghan Fitzgerald | Director | Sell | $16K (400 @ $40.45) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.